(Q44966806)

7 December 2017

title

Addition of montelukast or salmeterol to fluticasone for protection against asthma attacks: a randomized, double-blind, multicenter study (English)

1 reference

7 December 2017

0 references

Jonathan Ilowite

1

1 reference

7 December 2017

Robert Webb

2

1 reference

7 December 2017

Bruce Friedman

3

1 reference

7 December 2017

Edward Kerwin

4

1 reference

7 December 2017

Steven R Bird

5

1 reference

7 December 2017

Carolyn M Hustad

6

1 reference

7 December 2017

Jonathan M Edelman

7

1 reference

7 December 2017

publication date

1 June 2004

1 reference

Annals of Allergy, Asthma & Immunology

7 December 2017

published in

1 reference

7 December 2017

volume

92

1 reference

7 December 2017

issue

6

1 reference

7 December 2017

page(s)

641-648

1 reference

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

7 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Effect of long‐acting β2 agonists on exacerbation rates of asthma in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Montelukast: data from clinical trials in the management of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Leukotriene receptor antagonist, montelukast, can reduce the need for inhaled steroid while maintaining the clinical stability of asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Add-on therapy with montelukast or formoterol in patients with the glycine-16 beta2-receptor genotype

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Evaluation of salmeterol or montelukast as second-line therapy for asthma not controlled with inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Standardization of Spirometry, 1994 Update. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Validation of a standardized version of the Asthma Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Inhaled corticosteroids and bone density

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Effect of montelukast added to inhaled corticosteroids on fractional exhaled nitric oxide in asthmatic children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Determining a minimal important change in a disease-specific Quality of Life Questionnaire.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

Deleterious effects of inhaled beta-agonists: short-acting and long-acting agents differ

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961430-5

7 January 2021

10.1016/S1081-1206(10)61430-5

Identifiers

DOI

1 reference

7 December 2017

1 reference